Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B

Abstract

Long‐term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression. Therefore, current guidelines recommend the most potent drugs with optimal resistance profiles. Entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are the first‐line monotherapies for CHB. All of these drugs are highly effective in suppressing viral replication but with slightly different safety profiles. This review provides an overview of the long‐term efficacy and safety data that have become available over the 10 years since ETV and TDF were first approved for the treatment of chronic hepatitis, and recent data on TAF in patients with CHB.

 

KEYWORDS
chronic hepatitis B, efficacy, entecavir, safety, tenofovir alafenamide, tenofovir disoproxil fumarate, treatment

 

About Speaker

Maria BUTI FERRET

Professor of Medicine

Spain

City: Barcelona

Institution: Hospital Universitario Valle Hebron

Contact: 14100abf@comb.cat


Biography of Maria BUTI FERRET

Maria Buti earned her medical degree at the University of Barcelona and her PhD in Internal Medicine at the University “Autónoma” de Barcelona, Spain. She is currently Professor of Medicine and Chief of Internal  Medicine and Hepatology at the Hospital General Universitari Valle Hebron, Barcelona. Dr Butí has worked in viral hepatitis for the last 25  years, particularly in diagnosis and therapy of hepatitis B and C. She has been published widely in the field of liver disease, with numerous papers and contributions to books

Dr Butí is the Vicepresident of the Spanish Association for the Study of Liver Diseases, and an active member of the EASL, and  the AASLD and various professional societies.

View more